No association of CpG island methylator phenotype and colorectal cancer survival: population-based study

Min Jia¹, Lina Jansen¹, Viola Walter¹, Katrin Tagscherer²,³, Wilfried Roth²,³, Esther Herpel²,⁴, Matthias Kloor⁵, Hendrik Bläker⁶, Jenny Chang-Claude⁷, Hermann Brenner¹,⁸,⁹ and Michael Hoffmeister *,¹

¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; ²Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany; ³Institute of Pathology, University Medical Center Mainz, 55131 Mainz, Germany; ⁴NCT Tissue Bank, National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany; ⁵Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany; ⁶Institute of Pathology, Charité University Medicine, 10117 Berlin, Germany; ⁷Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ⁸Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany and ⁹German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

Background: Previous studies have shown adverse effects of CpG island methylator phenotype (CIMP) on colorectal cancer (CRC) prognosis. However, sample sizes were often limited and only few studies were able to adjust for relevant molecular features associated with CIMP. The aim of this study was to investigate the impact of CIMP on CRC survival in a large population-based study with comprehensive adjustment.

Methods: The CIMP status and other molecular tumour features were analysed in 1385 CRC patients diagnosed between 2003 and 2010. Detailed information were obtained from standardised personal interviews and medical records. During follow-up (median: 4.9 years), we assessed vital status, cause of death and therapy details. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of survival after CRC.

Results: The CIMP-H occurred more frequently in patients with older age, female gender, cancer in the proximal colon, BRAF mutation and microsatellite instability-high (MSI-H). However, CIMP status was not associated with CRC prognosis in CRC patients (HR = 1.00; 95% CI = 0.72–1.40 for overall survival; HR = 0.96; 95% CI = 0.65–1.41 for disease-specific survival) or in any of the subgroups. Although CIMP status was associated with the presence of MSI-H and BRAF mutation, the prognostic effects of MSI-H (HR = 0.49; 95% CI = 0.27–0.90) and BRAF mutation (HR = 1.78; 95% CI = 1.10–2.84) were independent of CIMP status. Similar benefit of chemotherapy was found for CRC outcomes in both the CIMP-low/negative group and the CIMP-high group.

Conclusions: CpG island methylator phenotype was not associated with CRC prognosis after adjusting for other important clinical factors and associated mutations.

Colorectal cancer (CRC), one of the most common malignant diseases worldwide, is a genetically and epigenetically heterogeneous disease (Jass, 2007; Leggett and Whitehall, 2010). One of epigenetic alterations of CRC is the hypermethylation of CpG islands in the promoter region of tumour-suppressor genes that could physically inhibit the binding of transcription factors and silence the expression of these genes. This subgroup of CRC was firstly introduced by Toyota et al (1999)
and defined as CpG island methylator phenotype (CIMP) (Kim and Deng, 2007).

Since then, CIMP was found to be associated with not only altered molecular characteristics (such as microsatellite instability (MSI) and BRAF mutation) and distinct clinical features such as older age, female gender, proximal location and poor differentiation of CRC (Weisenberger et al, 2006; Dahlin et al, 2010), but also with the prognosis of CRC. Findings for the latter are conflicting. Even though a meta-analysis was conducted on the prognostic value of CIMP among CRC patients concluding that CIMP positivity (CIMP+) or CIMP-high (CIMP-H) was an indicator for poor prognosis (Juo et al, 2014), the sample sizes of the included studies were limited (<500 for the majority of studies) and several important factors, such as MSI and BRAF mutation that are closely associated with both CIMP and CRC survival, were only adjusted for in a few included studies. So far, studies on the association between subtypes defined by CIMP and CRC prognosis considering other molecular tumour features were limited and the results were also conflicting (Kim et al, 2009; Ogin et al, 2009; Sanchez et al, 2009). Therefore, the aim of this study was to investigate the impact of CIMP on CRC survival in a large population-based study with comprehensive adjustment for clinical and pathological factors.

MATERIALS AND METHODS

Study population and follow-up. The patient cohort was derived from a large ongoing population-based case-control study on CRC conducted in southwestern Germany, with long-term follow-up of cases (DACHS: Darmkrebs: Chancen der Verhütung durch Screening). More details on the study design and participation rates have been described before (Brenner et al, 2014; Hoffmeister et al, 2015). In brief, patients were recruited in 22 hospitals of the Rhine–Neckar–Odenwald region and were eligible to participate if they had histologically confirmed CRC (ICD-10 codes C18-C20), were at least 30 years old and were physically and mentally able to participate in a personal interview of ~1 h in German. In this analysis, only patients recruited between 2003 and 2010 with complete information on important clinical and molecular factors (age, sex, tumour location, cancer stage, CIMP, MSI and BRAF mutation status) were included. The study was approved by the ethics committees of the Medical Faculty of the University of Heidelberg and of the Medical Chambers of Baden-Wuerttemberg and Rhineland-Palatinate.

Information from patients was collected by trained interviewers during face-to-face interviews using a standardised questionnaire including questions on sociodemographic information, lifestyle factors and medical history. In addition, discharge letters, pathology reports and endoscopy reports were collected at baseline. At ~3 years after diagnosis, information on CRC therapy, recurrence and diagnosis of concomitant diseases was obtained from the physicians of the patients with a standardised questionnaire. At ~5 years after diagnosis, this information was updated and a questionnaire was requested from the survivors. In addition, data on vital status and death dates were collected from the population registration offices and causes of death were verified by death certificates from the health authorities. More information on data collection and follow-up has been reported previously (Jansen et al, 2014; Hoffmeister et al, 2015).

Tumour sample analyses. Routine formalin-fixed, paraffin-embedded (FFPE) tumour samples from the patients enrolled were requested and used for tumour tissue analyses. The DNA was isolated from tumour samples under microscopic control of unstained slides and was prepared using the DNeasy tissue kit (Qiagen, Hilden, Germany) (Warth et al, 2011). After bisulphite conversion using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA), genomic DNA was analysed by methylation-specific PCR for the following CIMP loci: MLH1, MINT1, MINT2, MINT31 and MGMT. The PCR conditions and primers were used as previously described (Esteller et al, 1999; Chan et al, 2002; Park et al, 2003). The CIMP status was defined according to the number of hypermethylated loci: hypermethylation at 3 or more loci was classified as CIMP-high, methylation at 1 or 2 loci was classified as CIMP-low (CIMP-L) and if none of the loci was methylated, CIMP status was negative (CIMP-N). A mononucleotide marker panel (BAT25, BAT26 and CAT25) was used to screen for MSI-high (MSI-H) (Findeisen et al, 2005). In most tumour samples, KRAS mutation was determined by single-stranded conformational polymorphism technique (SSCP) using the same DNA sample, and expression of BRAF V600E was determined by immunohistochemical analyses in sections of tissue microarray blocks and evaluated by two pathologists independently (Blaker et al, 2004). In the remaining tumour samples, KRAS mutation (N = 178) and BRAF mutation (N = 242) were determined by Sanger sequencing: exon 2 of KRAS and exon 15 of BRAF were amplified by PCR using FidelliTaq polymerase (Affymetrix, Santa Clara, CA, USA) and the following primers: KRAS fw: 5’-GTGGACATGTCTTAACTATAGCTA-3’ and KRAS rv: 5’-GAATGGTTCCTGCACCATGAA-3’; BRAF fw: 5’-TGTTGTCTGCTGTAGGAAATG-3’ and BRAF rv: 5’-AGCATCTCAGGGCCAAATAATG-3’. After purification, Sanger sequencing was performed using the BigDye Terminator v1.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA, USA) according to standard protocols. Samples were sequenced on an ABI 3500 Genetic Analyzer (Life Technologies).

Statistical Analyses. The distribution of patient characteristics was compared between patients with CIMP-H and patients with CIMP-L/N by x² test and t-test. Adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs) of overall survival (OS) and disease-specific survival (DSS) were analysed by Cox regression. Potential covariates including age at diagnosis, sex, education level, family history of CRC, physical activity, body mass index, alcohol consumption, smoking status, ever use of nonsteroidal anti-inflammatory drugs (NSAIDs), ever use of statins, ever use of hormone replacement therapy, cancer stage, tumour location, tumour histologic grade, tumour resection, chemotherapy, MSI status and KRAS and BRAF mutation status were considered for inclusion in the final model. Covariates differentially distributed according to CIMP status with a P-value of <0.05 were chosen for the final model. According to this, clinical factors including age, sex, education level, alcohol consumption, tumour location, cancer stage, number of invaded lymph nodes, use of hormone replacement therapy, use of chemotherapy and molecular features including MSI status and BRAF mutation status were included in the final model. The proportional hazards assumption was tested via inclusion of time-dependent variables in the adjusted model that were kept in the final model if required for the proportional hazards assumption to hold. In addition, a correction for late entry that was defined as the potentially delayed time period between date of diagnosis and date of enrolment was also included in the final model. All analyses were performed with SAS, software version 9.4 (SAS Institute Inc., Cary, NC, USA). Tests of statistical significance were defined as two sided at an α-level of 0.05.

RESULTS

Study population. Of the 3146 patients diagnosed with CRC between 2003 and 2010 in the DACHS study, methylation data of all five CIMP markers were available for 1751 patients. Among them, tumour tissue samples of 1385 patients had complete information on Braf mutation and MSI-H at the time of this analysis. Patients finally included in this analysis were on average...
### Table 1. Characteristics of the study population by CIMP status

| Characteristics                                      | Total (n = 1385) | CIMP-low/negative (n = 1196) | CIMP-high (n = 189) | P-value* |
|------------------------------------------------------|------------------|-------------------------------|---------------------|----------|
| Age, n (%)                                           |                  |                               |                     |          |
| ≤65 Years                                            | 501 (36)         | 450 (38)                      | 51 (27)             | 0.0001   |
| 66–74 Years                                          | 456 (33)         | 401 (34)                      | 55 (29)             |          |
| 75+ Years                                            | 428 (31)         | 345 (29)                      | 83 (44)             |          |
| Sex, n (%)                                           |                  |                               |                     |          |
| Female                                               | 599 (43)         | 495 (41)                      | 104 (55)            | 0.0004   |
| Male                                                 | 786 (57)         | 701 (59)                      | 85 (45)             |          |
| Education, n (%)                                      |                  |                               |                     |          |
| Low                                                  | 890 (64)         | 753 (63)                      | 137 (73)            | 0.0186   |
| Medium                                               | 273 (20)         | 241 (20)                      | 32 (17)             |          |
| High                                                 | 221 (16)         | 202 (17)                      | 19 (10)             |          |
| Family history of CRC, n (%)                         |                  |                               |                     | 0.9940   |
| Lifetime regular active smoking, n (%)               |                  |                               |                     |          |
| None                                                 | 587 (42)         | 503 (42)                      | 84 (44)             | 0.7288   |
| <20 Pack-years                                       | 481 (35)         | 420 (35)                      | 61 (32)             |          |
| 20+ Pack-years                                       | 314 (23)         | 270 (23)                      | 44 (23)             |          |
| Alcohol consumption, mean (g per day)*               | 18.3             | 18.8                          | 14.9                | 0.0180   |
| Body mass index, mean (kg m⁻²)                       | 26.5             | 26.5                          | 26.8                | 0.2868   |
| Physical activity, mean (lifetime METs, h per week)#  | 235.5            | 237.8                         | 220.9               | 0.1107   |
| Regular use of NSAIDs, n (%)                         |                  |                               |                     | 0.6310   |
| Regular use of statins, n (%)                        | 174 (13)         | 152 (13)                      | 22 (12)             | 0.6928   |
| Regular use of hormone replacement therapy, n (%)    | 181 (13)         | 144 (12)                      | 37 (20)             | 0.0045   |
| Tumour location, n (%)                               |                  |                               |                     |          |
| Proximal colon                                       | 492 (36)         | 370 (31)                      | 122 (65)            |          |
| Distal colon                                         | 375 (27)         | 342 (29)                      | 33 (17)             |          |
| Rectum                                               | 517 (37)         | 483 (40)                      | 34 (18)             | <0.0001  |
| Cancer stage, n (%)                                  |                  |                               |                     |          |
| I                                                     | 255 (18)         | 220 (18)                      | 35 (19)             |          |
| II                                                    | 466 (34)         | 391 (33)                      | 75 (40)             |          |
| III                                                   | 467 (34)         | 411 (34)                      | 56 (30)             |          |
| IV                                                    | 197 (14)         | 174 (15)                      | 23 (12)             | 0.2502   |
| No. of invaded lymph node, n (%)                     |                  |                               |                     |          |
| ≤12                                                   | 386 (28)         | 345 (29)                      | 41 (22)             | 0.0012   |
| 12–20                                                | 653 (47)         | 572 (48)                      | 81 (43)             |          |
| 20+                                                  | 346 (25)         | 279 (23)                      | 67 (35)             |          |
| Surgery, n (%)                                       | 1378 (99)        | 1189 (99)                     | 189 (100)           | 0.2917   |
| Chemotherapy, n (%)                                   | 626 (45)         | 555 (47)                      | 71 (38)             | 0.0200   |
| KRAS mutation, n (%)                                 |                  |                               |                     |          |
| Negative                                             | 859 (68)         | 731 (68)                      | 128 (71)            | 0.3524   |
| Positive                                             | 402 (32)         | 350 (32)                      | 52 (29)             |          |
| BRAF mutation, n (%)                                 |                  |                               |                     | <0.0001  |
| Negative                                             | 1284 (93)        | 1149 (96)                     | 135 (71)            |          |
| Positive                                             | 101 (7)          | 47 (4)                        | 54 (29)             |          |
| Microsatellite instability, n (%)                    |                  |                               |                     | <0.0001  |
| MSS                                                  | 1247 (90)        | 1137 (95)                     | 110 (58)            |          |
| MSI-H                                                | 138 (10)         | 59 (5)                        | 79 (42)             |          |

Abbreviations: CIMP = CpG island methylator phenotype; CRC = colorectal cancer; MET = metabolic equivalent task; MSI-H = microsatellite instability-high; MSS = microsatellite stable; NSAID = nonsteroidal anti-inflammatory drug.

*Derived from Pearson’s χ² test of independence between covariables and CIMP status.

1Missing data for 1 patient.
2Missing data for 5 patients.
3Missing data for 3 patients.
4Missing data for 9 patients.
5Missing data for 8 patients.
6Missing data for 31 patients.
7Missing data for 15 patients.
8Missing data for 3 patients.
9Missing data for 6 patients.
10Missing data for 124 patients.

**Association of CIMP and CRC survival**

BRITISH JOURNAL OF CANCER
www.bjcancer.com | DOI:10.1038/bjc.2016.361

1361
69 years old and 43% were female. Almost all participants had surgery after diagnosis (99%) and 45% of the participants had chemotherapy before or after surgery. Median follow-up time was 4.9 years (interquartile range = 3.6–5.1 years).

Of the 1385 patients, 189 (13.6%) showed simultaneous hypermethylation at three or more of the five CIMP loci (Table 1). CIMP-H occurred more frequently in patients with older age, female gender, cancer in the proximal colon, BRAF mutation and MSI-H, consistent with the results reported previously (Issa, 2004; Samowitz et al, 2005a). Besides, CIMP-H was found associated with lower education level, lower alcohol consumption and more frequent lymph node invasion in this study (Table 1).

**CIMP and CRC prognosis.** After adjusting for major confounders, CIMP status was associated with neither OS (HR = 1.00; 95% CI = 0.72–1.40) nor DSS (HR = 0.96; 95% CI = 0.65–1.41) in CRC patients (Table 2). No differences were also observed for CIMP-H patients compared with CIMP-L or with CIMP-N patients, or for CIMP-L patients compared with CIMP-N patients (data not shown). In addition, analyses for hypermethylation in each of the CIMP loci did not show any association with CRC survival either, except for MINT 31 (Supplementary Table S1). No meaningful association between CIMP status and CRC prognosis was found in analyses further stratified by age, sex, tumour location and cancer stage (Table 2).

Combinations of other molecular features and CIMP status were assessed using the same multivariable Cox regression model (Table 3). Regardless of CIMP status, MSI-H was associated with significantly longer DSS (HR = 0.49; 95% CI = 0.27–0.90). Additional consideration of CIMP status yielded very similar HRs. Contrarily, BRAF mutation was similarly associated with poorer DSS (HR = 1.78; 95% CI = 1.10–2.84) with and without consideration of CIMP status. The KRAS mutation and subtypes of CIMP combined with KRAS were not associated with CRC prognosis.

**CIMP, chemotherapy and CRC prognosis.** As chemotherapy is generally not administrated to patients with stage I CRC, analyses on the prognostic value of chemotherapy among CRC patients with different CIMP status were only conducted among stage II to IV CRC patients (Table 4). For CRC patients with CIMP-L/N, chemotherapy was strongly associated with better OS (HR = 0.59; 95% CI = 0.43–0.79) and DSS (HR = 0.57; 95% CI = 0.40–0.80). Although not statistically significant, a similar benefit was observed for CRC patients with CIMP-H (HR = 0.66; 95% CI = 0.25–1.78 for OS and HR = 0.54; 95% CI = 0.15–1.88 for DSS). In analyses further stratified by stage, similar positive effects of chemotherapy were observed in both CIMP-L/N patients and CIMP-H patients.

**DISCUSSION**

In this population-based study, CIMP status was associated with all expected patient and tumour characteristics among CRC patients such as older age, female gender, proximal colon location, MSI-H...
The CIMP status did not show any relationship with CRC prognosis. This finding is not in line with the conclusion of a previous systematic review and meta-analysis (Juo et al. 2014). However, only three studies included in the meta-analysis took both BRAF mutation and MSI into account as confounders in their multivariable analyses (Ogino et al, 2009; Samowitz et al, 2009; Donada et al, 2013). Only in the study by Ogino et al (2009) that used three levels of CIMP (CIMP-H, CIMP-L and CIMP-N), CIMP-H was found to be associated with better DSS compared with CIMP-N CRC. The two other studies did not observe significant associations between CIMP (CIMP-H compared with CIMP-L/N) and CRC survival. In addition, Donada et al (2013) only analysed stage II colon cancer patients (N=120), and Samowitz et al (2009) investigated the association between CIMP and rectal cancer only among 990 patients. With a much bigger sample of unselected CRC patients (N=1385) and consideration of many potential confounders, our study did not find an association with CRC survival either. Although CIMP was still not associated with CRC survival even without adjustment for BRAF mutation and MSI in our study (data not shown), BRAF mutation and MSI should be considered as confounders in future CRC survival analyses.

Regarding chemotherapy, no obvious difference was found for the survival benefit associated with chemotherapy in the different CIMP groups, although the protective effect of chemotherapy was significant in patients with CIMP-L/N CRC only. A very similar effect was estimated for patients with CIMP-H CRC, although results were not statistically significant given the much lower number of patients. Results of previous studies on the role of chemotherapy in CIMP status subgroups were inconsistent. Li et al (2014) did not find an association between chemotherapy and OS for both CIMP-H and CIMP-L/N patients. Jover et al (2011) found that among stage II and III CRC patients chemotherapy was associated with significantly better DSS among CIMP-L/N patients (HR = 0.4; 95% CI = 0.2–0.6) but not among CIMP-H CRC patients (HR = 0.8; 95% CI = 0.3–2.0). However, the sample size with only 89 CIMP-H patients was rather small for the latter analysis. In addition, none of the associated molecular tumour features were adjusted for in either one of these studies. We found no evidence that chemotherapy could be differentially associated with CRC prognosis according to CIMP status, but this finding should be confirmed in other large studies.

Table 3. Associations of CIMP in combination with microsatellite instability, BRAF mutation and KRAS mutation with survival among CRC patients

| Factor | N | Deaths (%) | HR | 95% CI | Deaths (%) | HR | 95% CI |
|--------|---|------------|----|--------|------------|----|--------|
| CIMP-L/N and MSS | 1113 | 320 (29) | 1.00 | Reference | 250 (22) | 1.00 | Reference |
| CIMP-H and MSS | 108 | 35 (32) | 1.02 | 0.71–1.46 | 26 (24) | 0.92 | 0.61–1.40 |
| CIMP-L/N and MS-H | 57 | 10 (18) | 0.80 | 0.42–1.53 | 4 (7) | 0.42 | 0.15–1.14 |
| CIMP-H and MS-H | 79 | 17 (22) | 0.75 | 0.43–1.32 | 9 (11) | 0.54 | 0.26–1.12 |
| Any CIMP and MS-H | 136 | 27 (20) | 0.77 | 0.49–1.21 | 13 (10) | 0.49 | 0.27–0.90 |
| CIMP-L/N and BRAF+ | 1125 | 313 (28) | 1.00 | Reference | 239 (21) | 1.00 | Reference |
| CIMP-H and BRAF+ | 133 | 40 (30) | 1.08 | 0.77–1.53 | 25 (19) | 0.96 | 0.62–1.46 |
| CIMP-L/N and BRAF+ | 45 | 17 (38) | 1.50 | 0.90–2.49 | 15 (33) | 1.80 | 1.04–3.11 |
| CIMP-H and BRAF+ | 54 | 12 (22) | 0.99 | 0.51–1.94 | 10 (19) | 1.73 | 0.82–3.66 |
| Any CIMP and BRAF+ | 99 | 29 (29) | 1.28 | 0.82–1.98 | 25 (25) | 1.78 | 1.10–2.84 |
| CIMP-L/N and KRAS+ | 712 | 191 (27) | 1.00 | Reference | 147 (21) | 1.00 | Reference |
| CIMP-H and KRAS+ | 128 | 41 (32) | 1.08 | 0.73–1.59 | 28 (22) | 0.99 | 0.62–1.56 |
| CIMP-L/N and KRAS+ | 346 | 106 (31) | 1.12 | 0.88–1.43 | 82 (24) | 1.08 | 0.82–1.43 |
| CIMP-H and KRAS+ | 50 | 9 (18) | 0.81 | 0.41–1.43 | 5 (10) | 0.61 | 0.24–1.53 |
| Any CIMP and KRAS+ | 396 | 115 (29) | 1.09 | 0.86–1.38 | 87 (22) | 1.04 | 0.79–1.36 |

Abbreviations: BRAF+ = BRAF wild type; BRAF- = BRAF wild type; CI = confidence interval; CIMP = Cpg island methylator phenotype; CIMP-H = CIMP-high; CIMP-L/N = CIMP-low/negative; CRC = colorectal cancer; HR = hazard ratio; KRAS+ = KRAS mutation; KRAS- = KRAS wild type; MSI-H = microsatellite instability-high; MSS = microsatellite stability. *Adjusted for age, sex, education level, alcohol consumption, tumour location, cancer stage, number of invaded lymph nodes, usage of hormone replacement therapy, chemotherapy, microsatellite instability and BRAF mutation; additional adjustment for time-dependent effects of age and chemotherapy.
The current cohort was derived from a large population-based study including 1385 unselected patients with information on colorectal tumour characteristics that is, to our knowledge, the so far largest study on this topic. Furthermore, detailed information including sociodemographic data, lifestyle factors, clinical pathological and molecular factors were collected and relevant confounding factors were adjusted for in the multivariable analyses. Despite the large size of the total study population, the statistical power was still very limited in some of the subgroup analyses owing to the low prevalence of CIMP-H. Accordingly, even larger or pooled studies with detailed adjustment are needed.

In this study, the CIMP panel consisted of five markers and was different from the panels used in previous studies on CRC survival analyses. However, CIMP in general is only defined as a subgroup of CRC characterised by simultaneous hypermethylation of numerous CpG islands surrounding the promoter regions of several genes (Jover et al., 2011), and no specific markers or panels have been confirmed yet to be superior to the others. In fact, in previous studies there have been >50 genes used as CIMP markers and 16 CIMP panels that have been used to investigate the association between CIMP and CRC, and all of the five markers used in our CIMP definition were among the most commonly used markers (Ashktorab et al., 2013; Jia et al., 2016). In addition, with this CIMP definition, CIMP-H was found to be associated with all known patient and tumour characteristics of CIMP, such as older age, female gender, proximal colon location, BRAF mutation and MSI-H.

In conclusion, CIMP was not associated with CRC survival after adjusting for relevant clinical factors and prognostically relevant tumour characteristics that were associated with CIMP in this study. Associations found between chemotherapy and improved survival in CIMP-L/N CRC demand further research with larger sample sizes to also elucidate potential relationships in CIMP-H patients. Lack of adjustment may have contributed to findings of adverse effects of CIMP-H in CRC on CRC survival suggested by previous studies. Additional large cohort studies with comprehensive adjustment are required to investigate the prognostic value of CIMP using current or new definitions among CRC patients.

**ACKNOWLEDGEMENTS**

We thank the study participants and the interviewers who collected the data. We also thank the following hospitals and cooperating institutions that recruited patients for this study: Chirurgische Universitätsklinik Heidelberg, Klinik am Gesundbrunnen Heilbronn, St Vincentiuskrankenhaus Speyer, St Josefkrankenhaus Heidelberg, Chirurgische Universitätsklinik Mannheim, Diakonissenkrankenhaus Speyer, Krankenhaus Salem Heidelberg, Kreiskrankenhaus Schwetzingen, St Marienkrankenhaus Ludwigshafen, Klinikum Ludwigshafen, Stadtklinik Frankenthal, Diakoniekrankenhaus Mannheim, Kreiskrankenhaus Sinsheim, Klinikum am Plattenwald Bad Friedrichshall, Kreiskrankenhaus Weinheim, Kreiskrankenhaus Eberbach, Kreiskrankenhaus Buchen, Kreiskrankenhaus Mosbach, Enddarmzentrum Mannheim, Kreiskrankenhaus Brackenheim and Cancer Registry of Rhineland-Palatinate, Mainz. This work was supported by the German Research Council.

---

### Table 4. Association of chemotherapy with survival among CRC patients with different CIMP status

| Factor            | Overall survival* | Disease-specific survival* |
|-------------------|-------------------|---------------------------|
|                   | N                | Deaths (%)                | HR  | 95% CI                        | Deaths (%) | HR  | 95% CI |
| **Stages II–IV**  |                   |                            |     |                               |             |     |        |
| CIMP-H            | 82               | 20 (24)                   | 1.00| Reference                     | 12 (15)     | 1.00| Reference                 |
| Chemotherapy –    | 71               | 28 (39)                   | 0.66| 0.25–1.78                     | 23 (32)     | 0.54| 0.15–1.88                 |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |
| CIMP-L/N          | 305              | 58 (19)                   | 1.00| Reference                     | 34 (11)     | 1.00| Reference                 |
| Chemotherapy –    | 77               | 11 (14)                   | 1.10| 0.55–2.20                     | 7 (9)       | 1.17| 0.48–2.85                 |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |
| **Stage II**      |                   |                            |     |                               |             |     |        |
| CIMP-H            | 67               | 12 (18)                   | 1.00| Reference                     | 6 (9)       | 1.00| Reference                 |
| Chemotherapy –    | 7                | 0 (0)                     | NA  | NA                            | NA          |     | NA        |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |
| CIMP-L/N          | 85               | 38 (45)                   | 1.00| Reference                     | 29 (34)     | 1.00| Reference                 |
| Chemotherapy –    | 320              | 69 (22)                   | 0.67| 0.42–1.07                     | 54 (17)     | 0.63| 0.37–1.07                 |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |
| **Stage III**     |                   |                            |     |                               |             |     |        |
| CIMP-H            | 13               | 6 (46)                    | 1.00| Reference                     | 4 (31)      | 1.00| Reference                 |
| Chemotherapy –    | 43               | 10 (23)                   | 0.64| 0.11–3.62                     | 6 (14)      | 0.82| 0.07–9.46                |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |
| CIMP-L/N          | 25               | 24 (96)                   | 1.00| Reference                     | 22 (88)     | 1.00| Reference                 |
| Chemotherapy –    | 140              | 105 (75)                  | 0.32| 0.18–0.55                     | 100 (71)    | 0.34| 0.19–0.60                |
| Chemotherapy +    |                   |                            |     |                               |             |     |        |

Abbreviations: CI = confidence interval; CIMP = CpG island methylator phenotype; CIMP-H = CIMP-high; CIMP-L/N = CIMP-low/negative; CRC = colorectal cancer; HR = hazard ratio; NA = not available.

*Adjusted for age, sex, education level, alcohol consumption, tumour location, cancer stage, number of invaded lymph nodes, chemotherapy, microsatellite instability and BRAF mutation; additional adjustment for time-dependent effects of age and chemotherapy.
The authors declare no conflict of interest.

REFERENCES

Ashktorab H, Rahi H, Wansley D, Varma S, Shokrani B, Lee E, Daremipouran M, Laiyemo A, Goel A, Carethers JM, Brim H (2013) Toward a comprehensive and systematic methyleme signature in colorectal cancers. *Epigenetics* 8(8): 807–815.

Barras D (2015) BRAF mutation in colorectal cancer: an update. *Biomark Cancer* 7(Suppl 1): 9–12.

Blaker H, Helmchen B, Bonisch A, Aulmann S, Penzel R, Otto HF, Rieker RJ (2004) Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. *Scand J Gastroenterol* 39(8): 748–753.

Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M (2014) Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. *Gastroenterology* 146(3): 709–717.

Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A (2002) Concordant CpG island methylation in hyperplastic polyposis. *Am J Pathol* 160(2): 529–536.

Dahlin AM, Palmqvist R, Henrikkson ML, Jacobsson M, Eklof V, Rutegard J, Oberg A, Van Guelpen BR (2010) The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. *Clin Cancer Res* 16(6): 1845–1855.

Donada M, Bonin S, Barbazza R, Petrirosso D, Stanta G (2013) Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. *BMC Gastroenterol* 13: 36.

Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. *Cancer Res* 59(4): 793–797.

Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Brenner A, Donodog B, Pavlita M, Dippold W, Wagner R, Gebert J, von Knebel Doeberitz M (2005) T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. *Cancer Res* 65(18): 8072–8078.

Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E (2010) Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. *Eur J Cancer* 46(15): 2788–2798.

Hoffmeister M, Jansen L, Rudolph A, Toth C, Kloor M, Roth W, Blaker H, Jover R, Nguyen TP, Perez-Carbonell L, Zapater P, Paya A, Alenda C, Rojas E, Cubiella J, Balague F, Morellas JD, Clofent J, Bujanda L, Rene JM, Bessa X, Nicola RM, Nicolas-Perez D, Castells A, Andreu M, Llor X, Beland CR, Goel A (2011) 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. *Gastroenterology* 140(4): 1174–1181.

Kim HS, Heo JS, Lee J, Lee JY, Lee MY, Lim SH, Lee WY, Kim SH, Park YA, Cho YR, Yun SH, Kim ST, Park JO, Lim HY, Choi YS, Kwon WI, Kim HC, Park YS (2016) The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. *BMC Cancer* 16(1): 120.

Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH (2009) Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. *Virochova* (455): 485–494.

Kim YS, Deng G (2007) Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. *Nat Liver* 1(1): 1–11.

Leggett B, Whitehall V (2010) Role of the serrated pathway in colorectal cancer pathogenesis. *Gastroenterology* 138(6): 2088–2100.

Li X, Hu F, Wang Y (2014) CpG island methylator phenotype and prognosis of colorectal cancer in northeast China. *Biomed Res Int* 2014: 236361.

Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndbuusi MI, Nathanson DR, Ott J, Barany F, Paty PB (2010) KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. *Ann Surg Oncol* 17(2): 416–424.

Nosko K, Irahana N, Shima K, Kirsner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S (2008) Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. *PloS One* 3(11): e3698.

Ogino S, Nosko K, Kirsner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. *Nat* 50(1): 90–96.

Pajk SJ, Rashid A, Lee JH, Kim SG, Hamilton SR, Wu TT (2003) Frequent CpG island methylation in serrated adenomas of the colon. *Am J Pathol* 162(3): 815–822.

Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, Baron JA, Ahnen DJ, Win AK, Potter JD, Newcomb PA (2012) BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. *Cancer Epidemiol Biomarkers Prev* 21(10): 1792–1798.

Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, Potter JD, Newcomb PA (2013) KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer* 108(8): 1757–1764.

Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML (2005a) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. *Gastroenterology* 129(3): 837–845.

Samowitz WS, Curtin K, Wolff RK, Tripp SR, Caan BJ, Slattery ML (2009) Microsatellite instability and survival in rectal cancer. *Cancer Causes Control* 20(9): 1763–1768.

Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML (2005b) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. *Cancer Res* 65(14): 6063–6070.

Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF (2009) Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. *Br J Surg* 96(10): 1196–1204.

Strand M, Prolla TA, Liskay RM, Petes TD (1993) Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. *Nature* 365(6443): 274–276.

Toyota M, Ahuja N, Oh-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci USA* 96(15): 8681–8686.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J (2011) Impact of BRAF mutation and microsatellite
instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20): 4623–4632.

Warth A, Kloor M, Schirmacher P, Blaker H (2011) Genetics and epigenetics of small bowel adenocarcinoma: the interactions of CIN, MSI, and CIMP. Mod Pathol 24(4): 564–570.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwender M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38(7): 787–793.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)